Analyst deems Novo Nordisk once-weekly insulin has blockbuster potential

Even so, the analyst from Danish bank Sydbank doesn’t think insulin icodec will reach the same level as the pharmaceutical giant’s popular GLP-1 drugs.
Photo: Niels Hougaard/ERH
Photo: Niels Hougaard/ERH
by marketwire, translated by daniel pedersen

Novo Nordisk’s experimental new type 2 diabetes insulin icodec has the potential to reach blockbuster heights, which is achieved once a drug generates more than USD 1bn within a financial year, assesses Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading